What Nectin Therapeutics does

Nectin Therapeutics is a privately held, clinical-stage biotechnology company founded in 2017 and headquartered in Jerusalem, Israel, with a US subsidiary in Fort Lee, NJ. The company develops next-generation immuno-oncology therapies targeting the nectin pathway—most notably PVR (CD155)—a checkpoint mechanism implicated in resistance to approved immune checkpoint inhibitors. Approximately 80% of cancer patients do not respond to existing IO drugs, and Nectin is explicitly positioned to address this resistance segment with first-in-class antibodies and antibody-drug conjugates (ADCs).

The company's core pipeline comprises three programs: NTX1088, a first-in-class anti-PVR monoclonal antibody currently in Phase 1a/1b trials both as monotherapy and in combination with MSD/Merck's Keytruda (pembrolizumab), with 91 patients enrolled and confirmed partial responses observed across gastric, bladder, NSCLC, head and neck, and melanoma indications; a portfolio of ADC candidates in IND-enabling studies for solid and hematological malignancies; and NTX3A13, a first-in-class multispecific antibody in lead-selection. The platform originated from research at Hebrew University of Jerusalem and University of Rijeka and has attracted strategic clinical and capital partnerships with MD Anderson, MSD/Merck, Immunome, and multiple Israeli and international biotech investors.

Nectin is pre-revenue with a stated model of advancing assets through clinical development toward licensing or commercialization. The company has raised approximately $46M in disclosed equity funding plus an EIC Accelerator grant, employs 11–50 staff, and distributes visibility primarily through scientific conference presentations (notably ASCO 2026), peer-reviewed publications, and pharma trade press. End customers are oncology patients with advanced solid tumors (and increasingly hematological malignancies), served indirectly via clinical trial sites and, post-approval, through pharmaceutical partnership channels rather than direct sales.

Name

Nectin Therapeutics

Legal name

Nectin Therapeutics Ltd

Website

https://nectintx.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

1–10 employees

Short description

Nectin Therapeutics is a clinical-stage Israeli biotech developing first-in-class immuno-oncology antibodies and ADCs that target the PVR (CD155) checkpoint to overcome resistance in advanced solid tumors and hematological malignancies, with lead asset NTX1088 in Phase 1.

Ownership category

akta.pro rank

Product category

Immuno-Oncology Therapeutics

akta.pro primary industry

Antibody-Drug Conjugates (ADCs) & Antibody Conjugates (HLAAAAAE)

akta.pro secondary industries

Immuno-Oncology & Immune Monitoring Biomarkers (TMB, MSI, MRD, immune profiling) (HLAAAMAK), Therapeutic Vaccines (cancer, chronic infection immunotherapy) (HLAAAEAB)

Keywords

• Immuno-oncology therapeutics
• Antibody-drug conjugates
• Monoclonal antibody development
• Cancer immunotherapy pipeline
• PVR checkpoint inhibitors

Headquarters

HQ city

Jerusalem

HQ country

Israel

HQ region

Middle East

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Clinical Stage Development: Pre-revenue biotech company. Generating revenue through successful clinical development, regulatory approvals, and eventual product commercialization or licensing deals with pharmaceutical partners.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Nectin Therapeutics develops a pipeline of immuno-oncology antibodies and antibody-drug conjugates targeting the nectin/PVR pathway to overcome resistance to existing cancer immunotherapies. Lead asset NTX1088 is a first-in-class anti-PVR (CD155) monoclonal antibody currently in Phase 1 clinical trials as monotherapy and in combination with pembrolizumab (Keytruda). The company also advances ADC candidates in IND-enabling studies and NTX3A13, a multispecific therapeutic antibody in lead selection.

Product overview

Nectin Therapeutics is a biotechnology company developing a diverse pipeline of targeted immunotherapies including novel immuno-oncology (IO) antibodies and antibody-drug conjugates (ADCs). The company's core products include NTX1088, a first-in-class anti-PVR monoclonal antibody currently in Phase 1 clinical trials; ADC Candidates undergoing IND-enabling studies for solid and hematological malignancies; and NTX3A13, a first-in-class multispecific therapeutic antibody in lead-selection stage. The company focuses on addressing resistance mechanisms to current immune oncology treatments.

Differentiator

Problem solved

Functional benefit

Products and services

• NTX1088 A first-in-class monoclonal antibody directed against PVR (CD155), a key immune checkpoint, currently in Phase 1 clinical trials as monotherapy and in combination with KEYTRUDA (pembrolizumab) for patients with advanced solid tumors.
• ADC Candidates Pipeline of first-in-class and best-in-class antibody-drug conjugate (ADC) therapies for solid and hematological malignancies; candidates have demonstrated robust tumor regression in multiple in vivo models and programs are undergoing IND-enabling studies.
• NTX3A13

Quantifiable outcome

• Confirmed partial responses observed in evaluable patients across multiple cancer types including gastric, bladder, NSCLC, head and neck, and melanoma
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Five partnerships are on record, tiered minor and core.

• ImmunomeminorStrategic or Co-development Partner · 1 January 2024Immunome partnered with Nectin to access Nectin's antibodies for next-generation ADC development, leveraging Nectin's novel antibody technology in ADC programs.
• MD Anderson Cancer CentercoreStrategic or Co-development Partner · 30 November 2022MD Anderson's VC arm joined the $25M Series A funding round and entered into clinical trial collaboration for NTX1088. The partnership involves conducting Phase 1 clinical trials at MD Anderson sites for the company's first-in-class anti-PVR immunotherapy.
• MSD (Merck)coreStrategic or Co-development Partner · 1 January 2022Entered clinical trial collaboration agreement with MSD (Merck) to study NTX1088 with KEYTRUDA (pembrolizumab). The combination therapy arm was added to the Phase 1 clinical trial to evaluate the anti-PVR candidate with Keytruda in advanced solid tumors.
• Hebrew University of JerusalemcoreStrategic or Co-development Partner · 1 January 2017Company established in 2017 based on seminal research conducted at Hebrew University of Jerusalem, with ongoing research collaboration. Technology addresses major escape mechanisms of current IO therapies.
• University of RijekacoreStrategic or Co-development Partner · 1 January 2017Company established based on seminal research conducted at University of Rijeka, contributing to the foundational science behind nectin pathway targeting therapies.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Compugen: Israel-based clinical-stage immuno-oncology biotech developing novel antibody therapeutics targeting the tumor microenvironment. Both companies emerged from Israeli academic research and pursue novel immune checkpoints, making them closely comparable in geography, stage, and therapeutic approach.
• Werewolf Therapeutics: Clinical-stage oncology biotech developing conditionally activated IO therapeutics, including INDUKINE molecules designed to overcome the limitations of approved checkpoint inhibitors. Comparable as a Phase 1/2 IO biotech targeting resistance mechanisms with platform technology.
• Arcus Biosciences: Clinical-stage IO biotech with a pipeline targeting adenosine, TIGIT, and PD-1 pathways with multiple combination strategies including anti-PD-1 partnerships. Comparable in targeting novel IO pathways, partnering with large pharma for combinations, and pursuing the IO-resistant patient population.
• Compass Therapeutics: Clinical-stage biotech developing bispecific antibodies and next-generation IO therapeutics, including CTX-009 (anti-DLL4/VEGF) and CTX-1121 (anti-CD19/CD20). Comparable in clinical-stage IO antibody development and combination strategies to overcome resistance to existing therapies.
• Surface Oncology: Clinical-stage IO biotech developing antibody therapeutics targeting the tumor microenvironment, including IL-27 and CD39 programs. Comparable as a smaller clinical-stage IO company focused on novel immune checkpoints with combination therapy approaches.
• Bolt Biotherapeutics: Clinical-stage biotech developing immune-stimulating antibody conjugates (ISACs) that combine tumor-targeting antibodies with immune stimulants. Comparable in developing novel antibody-based oncology therapeutics at clinical stage with platform technology for solid tumors.
• Pyxis Oncology: Clinical-stage oncology company developing antibody-drug conjugates (ADCs) and immuno-oncology therapeutics. Comparable in developing ADCs for solid tumors and IO combination approaches at similar clinical stage.

Emerging players

• Harpoon Therapeutics: Clinical-stage biotech developing T cell engagers (TriTACs) for solid tumor IO, recently acquired by Merck for approximately $680M. Comparable as a clinical-stage IO antibody developer with pharma acquisition appeal, particularly given Nectin's existing MSD collaboration.
• Maverick Therapeutics: Clinical-stage biotech developing conditionally active T cell engagers for solid tumors, including COBRA platform for tumor-specific activation. Comparable as a smaller platform-based antibody developer targeting solid tumors with novel immune engagement approaches.

Broad incumbents

• ImmunoGen: Established ADC-focused oncology company acquired by AbbVie for $10.1B in 2024. Comparable as an ADC developer targeting solid tumors with multiple clinical-stage programs; provides context for potential strategic exit value for Nectin's ADC platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/nectin-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds7 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nectin Therapeutics